

Financial Tear Sheet

Corporate Profile

Iovance Biotherapeutics (formerly traded as Lion Biotechnologies) is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). This approach, also known as adoptive T-cell therapy, was developed by Dr. Steven A. Rosenberg at the National Cancer Institute. In Phase 2 clinical trials conducted at the NCI, 56% and 24% of patients treated with this technology achieved objective and complete response criteria, respectively.

Our lead product candidate is an autologous, ready-to-infuse cell therapy, that has demonstrated distinctive efficacy in the treatment of metastatic melanoma.

In addition to metastatic malignant melanoma, carcinoma of the head and neck and cervical cancer our TIL therapy technology is potentially applicable to many other tumor types, including ovarian, breast, bladder, colorectal and other cancers. As we continue advancing our current clinical programs through the introduction of manufacturing and logistical efficiencies aimed at decreasing production time and optimizing distribution processes, we aim to establish TIL therapy as a revolutionary, accessible, mainline cancer therapy.

Primary IR Contact

Stern Investor Relations, Inc.

Sarah McCabe

Phone: 212-362-1200

E-mail:

sarah@sternir.com

Stock Performance

IOVA (Common Stock)

Exchange NASDAQ (US Dollar)

Price **\$9.41**

Change (%) **▼ 0.13 (1.36%)**

Volume 470,873

52 Week High \$19.90

52 Week Low \$7.70

Market Cap \$1,175,037,297

Rolling EPS -1.36

PE Ratio 0

Shares Outstanding 123,169,528

Data as of November 16, 2018 1:20 p.m. ET



Recent Headlines

November 13, 2018

[Iovance Biotherapeutics to Participate at November Investor Conferences](#)

November 6, 2018

[Iovance Biotherapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update](#)

November 6, 2018

[Iovance Biotherapeutics Announces Updated Phase 2 Clinical Data from the Lifileucel Metastatic Melanoma Trial at the Society for Immunotherapy of Cancer's 33rd Annual Meeting](#)

Upcoming Events

There are currently no events scheduled.

SEC Filings

Filing Date	Form
November 9, 2018	8-K
November 6, 2018	10-Q
November 6, 2018	8-K
October 25, 2018	8-K

Corporate Governance

Data provided by Nasdaq. Minimum 15 minutes delayed.

© 2017 Lion Biotechnologies, Inc. All Rights Reserved.